CROMSOURCE Announces Launch of COVID-19 Clinical Trial

VERONA, Italy, 7 April, 2020 /PRNewswire/ — CROMSOURCE, an international contract research organization (CRO) with its global headquarters in Verona, Italy, has announced that it has initiated its first COVID-19 trial on behalf of a European pharmaceutical company. This trial is expected to be performed in Italy, though additional studies are planned by CROMSOURCE for other countries in Europe as well as the United States.   

 

“The COVID-19 pandemic has created an unprecedented global health and economic crisis. While all the work we have done in the previous twenty-two years of our operations has been critical in improving and saving lives, we are particularly proud to play such an important role in developing a safe and effective treatment for COVID-19,” said Dr. Oriana Zerbini, Founder and CEO of CROMSOURCE. “The current global situation is humbling to us all, and we look forward to all global citizens returning to their daily routines.”

“In response to the COVID-19 situation CROMSOURCE immediately formed a multi-disciplinary operational task force to ensure we continue to manage ongoing projects effectively, according to the most up to date regulatory guidance and incorporating innovative approaches to trial management as required,” commented Kerry Dyson, Chief Operating Officer. “These steps also ensured our readiness to rapidly and effectively launch clinical trials for COVID-19 therapies, demonstrated by our support of this important new study.”

About CROMSOURCE

CROMSOURCE is an ISO-certified, international contract research organization providing a comprehensive portfolio of services to the pharmaceutical, biotechnology, and medical device industries. Specializing in clinical development and staffing solutions, we offer a flexible approach to ensure our clients’ unique needs are supported. CROMSOURCE is unparalleled in offering an End-to-End Guarantee covering trial timelines, enrollment, and price. CROMSOURCE operates offices across all regions of Europe and North America. For more information, visit www.cromsource.com.

Logo – http://mail.healthtechnologynet.com/wp-content/uploads/2020/04/CROMSOURCE_Logo.jpg

Contact Info
Margherita Mosconi 
margherita.mosconi@cromsource.com  
+39 045 8222 811

 

View original content:http://www.prnewswire.com/news-releases/cromsource-announces-launch-of-covid-19-clinical-trial-301036582.html

SOURCE CROMSOURCE

Staff

Recent Posts

DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE:…

5 hours ago

CranioSense Awarded $5.5 Million in Federal Grants to Validate Noninvasive Neurotech

BOSTON, Dec. 17, 2025 /PRNewswire/ -- CranioSense, Inc., a neurotechnology company developing the world's first noninvasive…

5 hours ago

Therap Services Announces 2026 National Conference Schedule: Highlighting New Tools, Best Practices, and Over 250 Specialized Sessions

TORRINGTON, Conn., Dec. 17, 2025 /PRNewswire/ -- Therap Services, the national leader in HIPAA-compliant electronic…

5 hours ago

Catalyst by Wellstar Launches Polysight, Bringing Real-Time AI to Healthcare Compliance

The startup was formed to address rising regulatory complexity in healthcare.ATLANTA, Dec. 17, 2025 /PRNewswire/…

5 hours ago

Rockbridge Growth Equity-backed ProSites Acquires GeniusVets, Creating a Comprehensive Veterinary Marketing Platform under its LifeLearn Brand

LifeLearn offers a full suite of website creation, digital marketing, client communications and education, and…

5 hours ago

CORRECTION: TruMerit and NAPNAP Team Up to Develop a Global Micro-credential for Pediatric Nursing Care

PHILADELPHIA, PA / ACCESS Newswire / December 17, 2025 / TruMerit, a worldwide leader in…

5 hours ago